_id
691857833c536f8df2317a4d
Ticker
0J9P.LSE
Name
Incyte Corp.
Exchange
LSE
Address
1801 Augustine Cut-Off, Wilmington, DE, United States, 19803
Country
UK
Sector
Industry
Currency
USD
Website
https://www.incyte.com
Description
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI (ruxolitinib) for the treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for treating relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a selective fibroblast growth factor receptor kinase inhibitor for the treatment of unresectable biliary tract cancer, metastatic cholangiocarcinoma, and myeloid/lymphoid neoplasms; ICLUSIG (ponatinib), a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma; and NIKTIMVO (axatilimab-csfr) for treating chronic graft-versus-host disease, as well as OPZELURA (ruxolitinib) cream for treating atopic dermatitis. Its clinical stage products include INCB123667 (CDK2) for ovarian cancer; INCB161734 (KRASG12D) for cancers; INCA33890 (TGFßR2xPD-1) for solid tumors; Ruxolitinib cream for mild to moderate hidradenitis suppurativa (HS); Povorcitinib for HS, nonsegmental vitiligo, prurigo nodularis, and asthma and chronic spontaneous urticaria; INCB000262 (MRGPRX2) and INCB000547 (MRGPRX4) for systemic immune and neuro-immune disorders; INCA034460 (anti-CD122) for vitiligo; and Zilurgisertib (ALK2) for fibrodysplasia ossificans progressive. It has collaboration with Genesis Therapeutics, Inc. The company sells its products to specialty and retail pharmacies, hospital pharmacies, and specialty distributors and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.
Last Close
111.99
Volume
166
Current Price
112
Change
1.1535
Last Updated
2026-01-08T14:07:07.573Z
Image
https://logo.clearbit.com/www.incyte.com
Ipo Date
-
Market Cap
2454702489600
Next Dividend Date
-
Dividend Frequency
-
Dividend Rate
-
Dividend Yield
0
Sentiment
-
Sentiment Sources
0
Current Quarter
2025-09-30
Revenue
1365980000
Cost Of Revenue
99000000
Gross Profit
1266980000
Operating Expenses
823462000
Operating Income
443518000
Interest Expense
592000
Pretax Income
482308000
Net Income
424169000
Eps
2.105799065675747
Dividends Per Share
-
Shares Outstanding
212808000
Income Tax Expense
58139000
EBITDA
506923000
Operating Margin
32.468850202784814
Total Other Income Expense Net
38790000
Cash
2455006000
Short Term Investments
474814000
Receivables
895890000
Inventories
449957000
Total Current Assets
4275667000
Property Plant Equipment
826789000
Total Assets
6330356000
Payables
1459790000
Short Term Debt
10386000
Long Term Debt
-
Total Liabilities
1679162000
Equity
4651194000
Bs_currency_symbol
-
Depreciation
24023000
Change In Working Capital
569944000
Cash From Operations
559389000
Capital Expenditures
14747000
Cash From Investing
-47416000
Cash From Financing
-12778000
Net Change In Cash
500036000
Cf_currency_symbol
-
PE
0.2684
PB
4.850377773965137
ROE
9.119572307669815
ROA
6.700555229437333
FCF
544642000
Fcf Percent
0.3987188685046633
Piotroski FScore
4
Health Score
78
Deep Value Investing Score
7.5
Defensive Investing Score
7
Dividend Investing Score
3
Economic Moat Investing Score
9
Garp Investing Score
7.5
Growth Investing Score
4
Momentum Investing Score
4
Net Net Investing Score
4
Quality Investing Score
8.5
Value Investing Score
7
Quarters > 0 > quarter
2025-09-30
Quarters > 0 > income Statement > revenue
1365980000
Quarters > 0 > income Statement > cost Of Revenue
99000000
Quarters > 0 > income Statement > gross Profit
1266980000
Quarters > 0 > income Statement > operating Expenses
823462000
Quarters > 0 > income Statement > operating Income
443518000
Quarters > 0 > income Statement > interest Expense
592000
Quarters > 0 > income Statement > pretax Income
482308000
Quarters > 0 > income Statement > net Income
424169000
Quarters > 0 > income Statement > eps
2.105799065675747
Quarters > 0 > income Statement > dividends Per Share
-
Quarters > 0 > income Statement > shares Outstanding
201429000
Quarters > 0 > income Statement > income Tax Expense
58139000
Quarters > 0 > income Statement > EBITDA
506923000
Quarters > 0 > income Statement > operating Margin
32.468850202784814
Quarters > 0 > income Statement > total Other Income Expense Net
38790000
Quarters > 0 > income Statement > currency_symbol
-
Quarters > 0 > balance Sheet > cash
2455006000
Quarters > 0 > balance Sheet > short Term Investments
474814000
Quarters > 0 > balance Sheet > receivables
895890000
Quarters > 0 > balance Sheet > inventories
449957000
Quarters > 0 > balance Sheet > total Current Assets
4275667000
Quarters > 0 > balance Sheet > property Plant Equipment
826789000
Quarters > 0 > balance Sheet > total Assets
6330356000
Quarters > 0 > balance Sheet > payables
1459790000
Quarters > 0 > balance Sheet > short Term Debt
10386000
Quarters > 0 > balance Sheet > long Term Debt
-
Quarters > 0 > balance Sheet > total Liabilities
1679162000
Quarters > 0 > balance Sheet > equity
4651194000
Quarters > 0 > balance Sheet > currency_symbol
-
Quarters > 0 > cash Flow > net Income
424169000
Quarters > 0 > cash Flow > depreciation
24023000
Quarters > 0 > cash Flow > change In Working Capital
569944000
Quarters > 0 > cash Flow > cash From Operations
559389000
Quarters > 0 > cash Flow > capital Expenditures
14747000
Quarters > 0 > cash Flow > cash From Investing
-47416000
Quarters > 0 > cash Flow > cash From Financing
-12778000
Quarters > 0 > cash Flow > net Change In Cash
500036000
Quarters > 0 > cash Flow > currency_symbol
-
Quarters > 0 > ratios > PE
2.105799065675747
Quarters > 0 > ratios > PB
4.850377773965137
Quarters > 0 > ratios > ROE
9.119572307669815
Quarters > 0 > ratios > ROA
6.700555229437333
Quarters > 0 > ratios > FCF
544642000
Quarters > 0 > ratios > Piotroski FScore
4
Quarters > 0 > ratios > fcf Percent
0.3987188685046633
Quarters > 0 > health Score
78
Quarters > 1 > quarter
2025-06-30
Quarters > 1 > income Statement > revenue
1215529000
Quarters > 1 > income Statement > cost Of Revenue
95685000
Quarters > 1 > income Statement > gross Profit
1119844000
Quarters > 1 > income Statement > operating Expenses
809020000
Quarters > 1 > income Statement > operating Income
310824000
Quarters > 1 > income Statement > interest Expense
594000
Quarters > 1 > income Statement > pretax Income
558012000
Quarters > 1 > income Statement > net Income
404999000
Quarters > 1 > income Statement > eps
2.037792335869259
Quarters > 1 > income Statement > dividends Per Share
-
Quarters > 1 > income Statement > shares Outstanding
198744000
Quarters > 1 > income Statement > income Tax Expense
153013000
Quarters > 1 > income Statement > EBITDA
581525000
Quarters > 1 > income Statement > operating Margin
25.571088801665777
Quarters > 1 > income Statement > total Other Income Expense Net
247188000
Quarters > 1 > income Statement > currency_symbol
-
Quarters > 1 > balance Sheet > cash
1954969000
Quarters > 1 > balance Sheet > short Term Investments
466769000
Quarters > 1 > balance Sheet > receivables
842892000
Quarters > 1 > balance Sheet > inventories
83423000
Quarters > 1 > balance Sheet > total Current Assets
3643701000
Quarters > 1 > balance Sheet > property Plant Equipment
827544000
Quarters > 1 > balance Sheet > total Assets
5821354000
Quarters > 1 > balance Sheet > payables
241094000
Quarters > 1 > balance Sheet > short Term Debt
10648000
Quarters > 1 > balance Sheet > long Term Debt
-
Quarters > 1 > balance Sheet > total Liabilities
1650451000
Quarters > 1 > balance Sheet > equity
4170903000
Quarters > 1 > balance Sheet > currency_symbol
-
Quarters > 1 > cash Flow > net Income
404999000
Quarters > 1 > cash Flow > depreciation
22919000
Quarters > 1 > cash Flow > change In Working Capital
-582963000
Quarters > 1 > cash Flow > cash From Operations
44741000
Quarters > 1 > cash Flow > capital Expenditures
19074000
Quarters > 1 > cash Flow > cash From Investing
-18872000
Quarters > 1 > cash Flow > cash From Financing
-11246000
Quarters > 1 > cash Flow > net Change In Cash
13426000
Quarters > 1 > cash Flow > currency_symbol
USD
Quarters > 1 > ratios > PE
2.037792335869259
Quarters > 1 > ratios > PB
5.336812675816244
Quarters > 1 > ratios > ROE
9.710103543525227
Quarters > 1 > ratios > ROA
6.9571271563282355
Quarters > 1 > ratios > FCF
25667000
Quarters > 1 > ratios > Piotroski FScore
3
Quarters > 1 > ratios > fcf Percent
0.021115909204963437
Quarters > 1 > health Score
60
Quarters > 2 > quarter
2025-03-31
Quarters > 2 > income Statement > revenue
1052897999
Quarters > 2 > income Statement > cost Of Revenue
89550000
Quarters > 2 > income Statement > gross Profit
963348000
Quarters > 2 > income Statement > operating Expenses
746608000
Quarters > 2 > income Statement > operating Income
216740000
Quarters > 2 > income Statement > interest Expense
660000
Quarters > 2 > income Statement > pretax Income
234190000
Quarters > 2 > income Statement > net Income
158203000
Quarters > 2 > income Statement > eps
0.7982108710020838
Quarters > 2 > income Statement > dividends Per Share
-
Quarters > 2 > income Statement > shares Outstanding
198197000
Quarters > 2 > income Statement > income Tax Expense
75987000
Quarters > 2 > income Statement > EBITDA
257212000
Quarters > 2 > income Statement > operating Margin
20.58508993329372
Quarters > 2 > income Statement > total Other Income Expense Net
17450000
Quarters > 2 > income Statement > currency_symbol
-
Quarters > 2 > balance Sheet > cash
1941722000
Quarters > 2 > balance Sheet > short Term Investments
466936000
Quarters > 2 > balance Sheet > receivables
823134000
Quarters > 2 > balance Sheet > inventories
63975000
Quarters > 2 > balance Sheet > total Current Assets
3507421000
Quarters > 2 > balance Sheet > property Plant Equipment
795251000
Quarters > 2 > balance Sheet > total Assets
5749365000
Quarters > 2 > balance Sheet > payables
195537000
Quarters > 2 > balance Sheet > short Term Debt
10476000
Quarters > 2 > balance Sheet > long Term Debt
-
Quarters > 2 > balance Sheet > total Liabilities
2081802000
Quarters > 2 > balance Sheet > equity
3667563000
Quarters > 2 > balance Sheet > currency_symbol
-
Quarters > 2 > cash Flow > net Income
158203000
Quarters > 2 > cash Flow > depreciation
22362000
Quarters > 2 > cash Flow > change In Working Capital
13019000
Quarters > 2 > cash Flow > cash From Operations
266067000
Quarters > 2 > cash Flow > capital Expenditures
3169000
Quarters > 2 > cash Flow > cash From Investing
1097000
Quarters > 2 > cash Flow > cash From Financing
-12676000
Quarters > 2 > cash Flow > net Change In Cash
253936000
Quarters > 2 > cash Flow > currency_symbol
USD
Quarters > 2 > ratios > PE
0.7982108710020838
Quarters > 2 > ratios > PB
6.052537884148138
Quarters > 2 > ratios > ROE
4.313572800249102
Quarters > 2 > ratios > ROA
2.7516604007573013
Quarters > 2 > ratios > FCF
262898000
Quarters > 2 > ratios > Piotroski FScore
4
Quarters > 2 > ratios > fcf Percent
0.24968990372257321
Quarters > 2 > health Score
63
Quarters > 3 > quarter
2024-12-31
Quarters > 3 > income Statement > revenue
1178698000
Quarters > 3 > income Statement > cost Of Revenue
105118000
Quarters > 3 > income Statement > gross Profit
1073579999
Quarters > 3 > income Statement > operating Expenses
776111000
Quarters > 3 > income Statement > operating Income
297469000
Quarters > 3 > income Statement > interest Expense
419000
Quarters > 3 > income Statement > pretax Income
313724000
Quarters > 3 > income Statement > net Income
201212000
Quarters > 3 > income Statement > eps
1.0191922926913277
Quarters > 3 > income Statement > dividends Per Share
-
Quarters > 3 > income Statement > shares Outstanding
197423000
Quarters > 3 > income Statement > income Tax Expense
112512000
Quarters > 3 > income Statement > EBITDA
336876000
Quarters > 3 > income Statement > operating Margin
25.237083629564143
Quarters > 3 > income Statement > total Other Income Expense Net
16255000
Quarters > 3 > income Statement > currency_symbol
-
Quarters > 3 > balance Sheet > cash
1687829000
Quarters > 3 > balance Sheet > short Term Investments
470263000
Quarters > 3 > balance Sheet > receivables
853154000
Quarters > 3 > balance Sheet > inventories
58872000
Quarters > 3 > balance Sheet > total Current Assets
3239030000
Quarters > 3 > balance Sheet > property Plant Equipment
794214000
Quarters > 3 > balance Sheet > total Assets
5444322000
Quarters > 3 > balance Sheet > payables
197465000
Quarters > 3 > balance Sheet > short Term Debt
10002000
Quarters > 3 > balance Sheet > long Term Debt
-
Quarters > 3 > balance Sheet > total Liabilities
1996694000
Quarters > 3 > balance Sheet > equity
3447628000
Quarters > 3 > balance Sheet > currency_symbol
-
Quarters > 3 > cash Flow > net Income
201212000
Quarters > 3 > cash Flow > depreciation
22733000
Quarters > 3 > cash Flow > change In Working Capital
83591000
Quarters > 3 > cash Flow > cash From Operations
381218000
Quarters > 3 > cash Flow > capital Expenditures
17384000
Quarters > 3 > cash Flow > cash From Investing
-21465000
Quarters > 3 > cash Flow > cash From Financing
20394000
Quarters > 3 > cash Flow > net Change In Cash
383605000
Quarters > 3 > cash Flow > currency_symbol
USD
Quarters > 3 > ratios > PE
1.0191922926913277
Quarters > 3 > ratios > PB
6.413504009133236
Quarters > 3 > ratios > ROE
5.836244513619219
Quarters > 3 > ratios > ROA
3.6958137303414453
Quarters > 3 > ratios > FCF
363834000
Quarters > 3 > ratios > Piotroski FScore
4
Quarters > 3 > ratios > fcf Percent
0.30867448659453056
Quarters > 3 > health Score
66
Annuals > 0 > quarter
2024-12-31
Annuals > 0 > income Statement > revenue
4241216999
Annuals > 0 > income Statement > cost Of Revenue
377716000
Annuals > 0 > income Statement > gross Profit
3863501000
Annuals > 0 > income Statement > operating Expenses
3783357000
Annuals > 0 > income Statement > operating Income
80144000
Annuals > 0 > income Statement > interest Expense
2280000
Annuals > 0 > income Statement > pretax Income
316630000
Annuals > 0 > income Statement > net Income
32615000
Annuals > 0 > income Statement > eps
0.1549185389255688
Annuals > 0 > income Statement > dividends Per Share
-
Annuals > 0 > income Statement > shares Outstanding
210530000
Annuals > 0 > income Statement > income Tax Expense
284015000
Annuals > 0 > income Statement > EBITDA
408158000
Annuals > 0 > income Statement > operating Margin
1.8896462977229522
Annuals > 0 > income Statement > total Other Income Expense Net
236486000
Annuals > 0 > income Statement > currency_symbol
-
Annuals > 0 > balance Sheet > cash
1687829000
Annuals > 0 > balance Sheet > short Term Investments
470263000
Annuals > 0 > balance Sheet > receivables
853154000
Annuals > 0 > balance Sheet > inventories
58872000
Annuals > 0 > balance Sheet > total Current Assets
3239030000
Annuals > 0 > balance Sheet > property Plant Equipment
794214000
Annuals > 0 > balance Sheet > total Assets
5444322000
Annuals > 0 > balance Sheet > payables
197465000
Annuals > 0 > balance Sheet > short Term Debt
10002000
Annuals > 0 > balance Sheet > long Term Debt
-
Annuals > 0 > balance Sheet > total Liabilities
1996694000
Annuals > 0 > balance Sheet > equity
3447628000
Annuals > 0 > balance Sheet > currency_symbol
-
Annuals > 0 > cash Flow > net Income
32615000
Annuals > 0 > cash Flow > depreciation
89248000
Annuals > 0 > cash Flow > change In Working Capital
138244000
Annuals > 0 > cash Flow > cash From Operations
335337000
Annuals > 0 > cash Flow > capital Expenditures
86263000
Annuals > 0 > cash Flow > cash From Investing
157517000
Annuals > 0 > cash Flow > cash From Financing
-2021547000
Annuals > 0 > cash Flow > net Change In Cash
-1525770000
Annuals > 0 > cash Flow > currency_symbol
-
Annuals > 0 > ratios > PE
0.1549185389255688
Annuals > 0 > ratios > PB
6.839299367565178
Annuals > 0 > ratios > ROE
0.9460127368730037
Annuals > 0 > ratios > ROA
0.5990644932463582
Annuals > 0 > ratios > FCF
249074000
Annuals > 0 > ratios > Piotroski FScore
4
Annuals > 0 > ratios > fcf Percent
0.0587270116239577
Annuals > 0 > health Score
45
Annuals > 1 > quarter
2023-12-31
Annuals > 1 > income Statement > revenue
3695649000
Annuals > 1 > income Statement > cost Of Revenue
315150000
Annuals > 1 > income Statement > gross Profit
3380499000
Annuals > 1 > income Statement > operating Expenses
2728727000
Annuals > 1 > income Statement > operating Income
651772000
Annuals > 1 > income Statement > interest Expense
2551000
Annuals > 1 > income Statement > pretax Income
834215000
Annuals > 1 > income Statement > net Income
597599000
Annuals > 1 > income Statement > eps
2.645086045111717
Annuals > 1 > income Statement > dividends Per Share
-
Annuals > 1 > income Statement > shares Outstanding
225928000
Annuals > 1 > income Statement > income Tax Expense
236616000
Annuals > 1 > income Statement > EBITDA
919426000
Annuals > 1 > income Statement > operating Margin
17.636198675794155
Annuals > 1 > income Statement > total Other Income Expense Net
182443000
Annuals > 1 > income Statement > currency_symbol
-
Annuals > 1 > balance Sheet > cash
3213376000
Annuals > 1 > balance Sheet > short Term Investments
442667000
Annuals > 1 > balance Sheet > receivables
743557000
Annuals > 1 > balance Sheet > inventories
62972000
Annuals > 1 > balance Sheet > total Current Assets
4645402000
Annuals > 1 > balance Sheet > property Plant Equipment
777048000
Annuals > 1 > balance Sheet > total Assets
6782107000
Annuals > 1 > balance Sheet > payables
109601000
Annuals > 1 > balance Sheet > short Term Debt
9125000
Annuals > 1 > balance Sheet > long Term Debt
-
Annuals > 1 > balance Sheet > total Liabilities
1592270000
Annuals > 1 > balance Sheet > equity
5189837000
Annuals > 1 > balance Sheet > currency_symbol
-
Annuals > 1 > cash Flow > net Income
597599000
Annuals > 1 > cash Flow > depreciation
82660000
Annuals > 1 > cash Flow > change In Working Capital
-248651000
Annuals > 1 > cash Flow > cash From Operations
496487000
Annuals > 1 > cash Flow > capital Expenditures
47486000
Annuals > 1 > cash Flow > cash From Investing
-207677000
Annuals > 1 > cash Flow > cash From Financing
-20033000
Annuals > 1 > cash Flow > net Change In Cash
262101000
Annuals > 1 > cash Flow > currency_symbol
USD
Annuals > 1 > ratios > PE
2.645086045111717
Annuals > 1 > ratios > PB
4.875670661718278
Annuals > 1 > ratios > ROE
11.514793239171095
Annuals > 1 > ratios > ROA
8.811406248825033
Annuals > 1 > ratios > FCF
449001000
Annuals > 1 > ratios > Piotroski FScore
3
Annuals > 1 > ratios > fcf Percent
0.12149449257762304
Annuals > 1 > health Score
73
Annuals > 2 > quarter
2022-12-31
Annuals > 2 > income Statement > revenue
3394635000
Annuals > 2 > income Statement > cost Of Revenue
253352000
Annuals > 2 > income Statement > gross Profit
3141283000
Annuals > 2 > income Statement > operating Expenses
2541721000
Annuals > 2 > income Statement > operating Income
599562000
Annuals > 2 > income Statement > interest Expense
2666000
Annuals > 2 > income Statement > pretax Income
529116000
Annuals > 2 > income Statement > net Income
340660000
Annuals > 2 > income Statement > eps
1.5210887755739915
Annuals > 2 > income Statement > dividends Per Share
26301000
Annuals > 2 > income Statement > shares Outstanding
223958000
Annuals > 2 > income Statement > income Tax Expense
188456000
Annuals > 2 > income Statement > EBITDA
599637000
Annuals > 2 > income Statement > operating Margin
17.66204614045398
Annuals > 2 > income Statement > total Other Income Expense Net
-70446000
Annuals > 2 > income Statement > currency_symbol
USD
Annuals > 2 > balance Sheet > cash
2951422000
Annuals > 2 > balance Sheet > short Term Investments
287543000
Annuals > 2 > balance Sheet > receivables
644879000
Annuals > 2 > balance Sheet > inventories
41995000
Annuals > 2 > balance Sheet > total Current Assets
4092850000
Annuals > 2 > balance Sheet > property Plant Equipment
765608000
Annuals > 2 > balance Sheet > total Assets
5840984000
Annuals > 2 > balance Sheet > payables
277546000
Annuals > 2 > balance Sheet > short Term Debt
11374000
Annuals > 2 > balance Sheet > long Term Debt
-
Annuals > 2 > balance Sheet > total Liabilities
1470865000
Annuals > 2 > balance Sheet > equity
4370119000
Annuals > 2 > balance Sheet > currency_symbol
USD
Annuals > 2 > cash Flow > net Income
340660000
Annuals > 2 > cash Flow > depreciation
67855000
Annuals > 2 > cash Flow > change In Working Capital
198810000
Annuals > 2 > cash Flow > cash From Operations
969941000
Annuals > 2 > cash Flow > capital Expenditures
77833000
Annuals > 2 > cash Flow > cash From Investing
-78542000
Annuals > 2 > cash Flow > cash From Financing
-794000
Annuals > 2 > cash Flow > net Change In Cash
893960000
Annuals > 2 > cash Flow > currency_symbol
USD
Annuals > 2 > ratios > PE
1.5210887755739915
Annuals > 2 > ratios > PB
5.739728368952883
Annuals > 2 > ratios > ROE
7.7952110686230744
Annuals > 2 > ratios > ROA
5.832236486181095
Annuals > 2 > ratios > FCF
892108000
Annuals > 2 > ratios > Piotroski FScore
4
Annuals > 2 > ratios > fcf Percent
0.2627993878576047
Annuals > 2 > health Score
76
Annuals > 3 > quarter
2021-12-31
Annuals > 3 > income Statement > revenue
2986267000
Annuals > 3 > income Statement > cost Of Revenue
187335000
Annuals > 3 > income Statement > gross Profit
2798932000
Annuals > 3 > income Statement > operating Expenses
2161395000
Annuals > 3 > income Statement > operating Income
637537000
Annuals > 3 > income Statement > interest Expense
1908000
Annuals > 3 > income Statement > pretax Income
570444000
Annuals > 3 > income Statement > net Income
948581000
Annuals > 3 > income Statement > eps
4.271463566198655
Annuals > 3 > income Statement > dividends Per Share
29940000
Annuals > 3 > income Statement > shares Outstanding
222074000
Annuals > 3 > income Statement > income Tax Expense
-378137000
Annuals > 3 > income Statement > EBITDA
630196000
Annuals > 3 > income Statement > operating Margin
21.34896176396819
Annuals > 3 > income Statement > total Other Income Expense Net
-67093000
Annuals > 3 > income Statement > currency_symbol
USD
Annuals > 3 > balance Sheet > cash
2057440000
Annuals > 3 > balance Sheet > short Term Investments
290752000
Annuals > 3 > balance Sheet > receivables
616300000
Annuals > 3 > balance Sheet > inventories
27904000
Annuals > 3 > balance Sheet > total Current Assets
3118674000
Annuals > 3 > balance Sheet > property Plant Equipment
751468000
Annuals > 3 > balance Sheet > total Assets
4933352000
Annuals > 3 > balance Sheet > payables
172110000
Annuals > 3 > balance Sheet > short Term Debt
13189000
Annuals > 3 > balance Sheet > long Term Debt
-
Annuals > 3 > balance Sheet > total Liabilities
1163348000
Annuals > 3 > balance Sheet > equity
3770004000
Annuals > 3 > balance Sheet > currency_symbol
USD
Annuals > 3 > cash Flow > net Income
948581000
Annuals > 3 > cash Flow > depreciation
57844000
Annuals > 3 > cash Flow > change In Working Capital
-14569000
Annuals > 3 > cash Flow > cash From Operations
749488000
Annuals > 3 > cash Flow > capital Expenditures
181006000
Annuals > 3 > cash Flow > cash From Investing
-207699000
Annuals > 3 > cash Flow > cash From Financing
6176000
Annuals > 3 > cash Flow > net Change In Cash
544395000
Annuals > 3 > cash Flow > currency_symbol
USD
Annuals > 3 > ratios > PE
4.271463566198655
Annuals > 3 > ratios > PB
6.597416872767244
Annuals > 3 > ratios > ROE
25.161273038437095
Annuals > 3 > ratios > ROA
19.2279204889495
Annuals > 3 > ratios > FCF
568482000
Annuals > 3 > ratios > Piotroski FScore
3
Annuals > 3 > ratios > fcf Percent
0.19036542948102095
Annuals > 3 > health Score
84
Valuation > metrics > PE
0.2684
Valuation > metrics > PB
4.850377773965137
Valuation > final Score
51.49622226034863
Valuation > verdict
17.8% Undervalued
Profitability > metrics > ROE
9.119572307669815
Profitability > metrics > ROA
9.920534035976141
Profitability > metrics > Net Margin
0.3105235801402656
Profitability > final Score
78
Profitability > verdict
Adequate
Risk > metrics > Debt Equity
0.36101740757319517
Risk > metrics > Interest Coverage
749.1858108108108
Risk > final Score
100
Risk > verdict
Low
Liquidity > metrics > Current Ratio
2.908268805911673
Liquidity > metrics > Quick Ratio
2.6022122521385196
Liquidity > final Score
100
Liquidity > verdict
Great
Prev Valuations > 0
46.63187324183756
Prev Valuations > 1
40
Prev Valuations > 2
40
Prev Profitabilities > 0
79
Prev Profitabilities > 1
45
Prev Profitabilities > 2
56
Prev Risks > 0
100
Prev Risks > 1
88
Prev Risks > 2
88
Prev Liquidities > 0
100
Prev Liquidities > 1
100
Prev Liquidities > 2
100
Updated At
2026-01-20T22:54:28.711Z
Earnings History > 0 > period
2026-03-31
Earnings History > 0 > report Date
2026-04-27
Earnings History > 0 > date
2026-03-31
Earnings History > 0 > before After Market
BeforeMarket
Earnings History > 0 > currency
-
Earnings History > 0 > eps Actual
-
Earnings History > 0 > eps Estimate
-
Earnings History > 0 > eps Difference
0
Earnings History > 0 > surprise Percent
-
Earnings History > 1 > period
2025-12-31
Earnings History > 1 > report Date
2026-02-09
Earnings History > 1 > date
2025-12-31
Earnings History > 1 > before After Market
BeforeMarket
Earnings History > 1 > currency
-
Earnings History > 1 > eps Actual
-
Earnings History > 1 > eps Estimate
1.89
Earnings History > 1 > eps Difference
0
Earnings History > 1 > surprise Percent
-
Earnings History > 2 > period
2025-09-30
Earnings History > 2 > report Date
2025-10-28
Earnings History > 2 > date
2025-09-30
Earnings History > 2 > before After Market
BeforeMarket
Earnings History > 2 > currency
-
Earnings History > 2 > eps Actual
2.1058
Earnings History > 2 > eps Estimate
1.64
Earnings History > 2 > eps Difference
0.4658
Earnings History > 2 > surprise Percent
28.4024
Earnings History > 3 > period
2025-06-30
Earnings History > 3 > report Date
2025-07-29
Earnings History > 3 > date
2025-06-30
Earnings History > 3 > before After Market
BeforeMarket
Earnings History > 3 > currency
-
Earnings History > 3 > eps Actual
2.0378
Earnings History > 3 > eps Estimate
1.47
Earnings History > 3 > eps Difference
0.5678
Earnings History > 3 > surprise Percent
38.6259
Earnings History > 4 > period
2025-03-31
Earnings History > 4 > report Date
2025-04-29
Earnings History > 4 > date
2025-03-31
Earnings History > 4 > before After Market
BeforeMarket
Earnings History > 4 > currency
-
Earnings History > 4 > eps Actual
0.7982
Earnings History > 4 > eps Estimate
-
Earnings History > 4 > eps Difference
0
Earnings History > 4 > surprise Percent
-
Earnings History > 5 > period
2024-12-31
Earnings History > 5 > report Date
2025-02-10
Earnings History > 5 > date
2024-12-31
Earnings History > 5 > before After Market
BeforeMarket
Earnings History > 5 > currency
-
Earnings History > 5 > eps Actual
1.0192
Earnings History > 5 > eps Estimate
-
Earnings History > 5 > eps Difference
0
Earnings History > 5 > surprise Percent
-
Earnings History > 6 > period
2024-09-30
Earnings History > 6 > report Date
2024-10-29
Earnings History > 6 > date
2024-09-30
Earnings History > 6 > before After Market
AfterMarket
Earnings History > 6 > currency
-
Earnings History > 6 > eps Actual
0.5436
Earnings History > 6 > eps Estimate
-
Earnings History > 6 > eps Difference
0
Earnings History > 6 > surprise Percent
-
Earnings History > 7 > period
2024-06-30
Earnings History > 7 > report Date
2024-07-30
Earnings History > 7 > date
2024-06-30
Earnings History > 7 > before After Market
AfterMarket
Earnings History > 7 > currency
-
Earnings History > 7 > eps Actual
-2.0378
Earnings History > 7 > eps Estimate
-
Earnings History > 7 > eps Difference
0
Earnings History > 7 > surprise Percent
-
Earnings History > 8 > period
2024-03-31
Earnings History > 8 > report Date
2024-04-30
Earnings History > 8 > date
2024-03-31
Earnings History > 8 > before After Market
AfterMarket
Earnings History > 8 > currency
-
Earnings History > 8 > eps Actual
0.7462
Earnings History > 8 > eps Estimate
-
Earnings History > 8 > eps Difference
0
Earnings History > 8 > surprise Percent
-
Earnings History > 9 > period
2023-12-31
Earnings History > 9 > report Date
2024-03-11
Earnings History > 9 > date
2023-12-31
Earnings History > 9 > before After Market
AfterMarket
Earnings History > 9 > currency
-
Earnings History > 9 > eps Actual
0.8892
Earnings History > 9 > eps Estimate
-
Earnings History > 9 > eps Difference
0
Earnings History > 9 > surprise Percent
-
Earnings History > 10 > period
2023-09-30
Earnings History > 10 > report Date
2023-12-11
Earnings History > 10 > date
2023-09-30
Earnings History > 10 > before After Market
AfterMarket
Earnings History > 10 > currency
-
Earnings History > 10 > eps Actual
0.7573
Earnings History > 10 > eps Estimate
-
Earnings History > 10 > eps Difference
0
Earnings History > 10 > surprise Percent
-
Earnings History > 11 > period
2023-06-30
Earnings History > 11 > report Date
2023-08-01
Earnings History > 11 > date
2023-06-30
Earnings History > 11 > before After Market
AfterMarket
Earnings History > 11 > currency
-
Earnings History > 11 > eps Actual
0.9021
Earnings History > 11 > eps Estimate
-
Earnings History > 11 > eps Difference
0
Earnings History > 11 > surprise Percent
-
Earnings History > 12 > period
2023-03-31
Earnings History > 12 > report Date
2023-05-02
Earnings History > 12 > date
2023-03-31
Earnings History > 12 > before After Market
AfterMarket
Earnings History > 12 > currency
-
Earnings History > 12 > eps Actual
0.0962
Earnings History > 12 > eps Estimate
-
Earnings History > 12 > eps Difference
0
Earnings History > 12 > surprise Percent
-
Earnings History > 13 > period
2022-12-31
Earnings History > 13 > report Date
2023-02-07
Earnings History > 13 > date
2022-12-31
Earnings History > 13 > before After Market
AfterMarket
Earnings History > 13 > currency
-
Earnings History > 13 > eps Actual
0.1266
Earnings History > 13 > eps Estimate
-
Earnings History > 13 > eps Difference
0
Earnings History > 13 > surprise Percent
-
Earnings History > 14 > period
2022-09-30
Earnings History > 14 > report Date
2022-11-01
Earnings History > 14 > date
2022-09-30
Earnings History > 14 > before After Market
AfterMarket
Earnings History > 14 > currency
-
Earnings History > 14 > eps Actual
0.5031
Earnings History > 14 > eps Estimate
-
Earnings History > 14 > eps Difference
0
Earnings History > 14 > surprise Percent
-
Earnings History > 15 > period
2022-06-30
Earnings History > 15 > report Date
2022-08-02
Earnings History > 15 > date
2022-06-30
Earnings History > 15 > before After Market
AfterMarket
Earnings History > 15 > currency
-
Earnings History > 15 > eps Actual
0.7218
Earnings History > 15 > eps Estimate
-
Earnings History > 15 > eps Difference
0
Earnings History > 15 > surprise Percent
-
Earnings History > 16 > period
2022-03-31
Earnings History > 16 > report Date
2022-05-03
Earnings History > 16 > date
2022-03-31
Earnings History > 16 > before After Market
BeforeMarket
Earnings History > 16 > currency
-
Earnings History > 16 > eps Actual
0.1704
Earnings History > 16 > eps Estimate
-
Earnings History > 16 > eps Difference
0
Earnings History > 16 > surprise Percent
-
Earnings History > 17 > period
2021-12-31
Earnings History > 17 > report Date
2022-02-08
Earnings History > 17 > date
2021-12-31
Earnings History > 17 > before After Market
BeforeMarket
Earnings History > 17 > currency
-
Earnings History > 17 > eps Actual
2.54
Earnings History > 17 > eps Estimate
-
Earnings History > 17 > eps Difference
0
Earnings History > 17 > surprise Percent
-
Earnings History > 18 > period
2021-09-30
Earnings History > 18 > report Date
2021-11-02
Earnings History > 18 > date
2021-09-30
Earnings History > 18 > before After Market
-
Earnings History > 18 > currency
-
Earnings History > 18 > eps Actual
0.8177
Earnings History > 18 > eps Estimate
-
Earnings History > 18 > eps Difference
0
Earnings History > 18 > surprise Percent
-
Earnings History > 19 > period
2021-06-30
Earnings History > 19 > report Date
2021-08-03
Earnings History > 19 > date
2021-06-30
Earnings History > 19 > before After Market
-
Earnings History > 19 > currency
-
Earnings History > 19 > eps Actual
0.6725
Earnings History > 19 > eps Estimate
-
Earnings History > 19 > eps Difference
0
Earnings History > 19 > surprise Percent
-
Earnings History > 20 > period
2021-03-31
Earnings History > 20 > report Date
2021-05-04
Earnings History > 20 > date
2021-03-31
Earnings History > 20 > before After Market
-
Earnings History > 20 > currency
-
Earnings History > 20 > eps Actual
0.2413
Earnings History > 20 > eps Estimate
-
Earnings History > 20 > eps Difference
0
Earnings History > 20 > surprise Percent
-
Earnings History > 21 > period
2020-12-31
Earnings History > 21 > report Date
2020-12-31
Earnings History > 21 > date
2020-12-31
Earnings History > 21 > before After Market
-
Earnings History > 21 > currency
-
Earnings History > 21 > eps Actual
0.6774
Earnings History > 21 > eps Estimate
-
Earnings History > 21 > eps Difference
0
Earnings History > 21 > surprise Percent
-
Earnings History > 22 > period
2020-09-30
Earnings History > 22 > report Date
2020-09-30
Earnings History > 22 > date
2020-09-30
Earnings History > 22 > before After Market
-
Earnings History > 22 > currency
-
Earnings History > 22 > eps Actual
-0.0695
Earnings History > 22 > eps Estimate
-
Earnings History > 22 > eps Difference
0
Earnings History > 22 > surprise Percent
-
Earnings History > 23 > period
2020-06-30
Earnings History > 23 > report Date
2020-06-30
Earnings History > 23 > date
2020-06-30
Earnings History > 23 > before After Market
-
Earnings History > 23 > currency
-
Earnings History > 23 > eps Actual
1.3169
Earnings History > 23 > eps Estimate
-
Earnings History > 23 > eps Difference
0
Earnings History > 23 > surprise Percent
-
Earnings History > 24 > period
2020-03-31
Earnings History > 24 > report Date
2020-03-31
Earnings History > 24 > date
2020-03-31
Earnings History > 24 > before After Market
-
Earnings History > 24 > currency
-
Earnings History > 24 > eps Actual
-3.3252
Earnings History > 24 > eps Estimate
-
Earnings History > 24 > eps Difference
0
Earnings History > 24 > surprise Percent
-
Earnings History > 25 > period
2019-12-31
Earnings History > 25 > report Date
2019-12-31
Earnings History > 25 > date
2019-12-31
Earnings History > 25 > before After Market
-
Earnings History > 25 > currency
-
Earnings History > 25 > eps Actual
0.5079
Earnings History > 25 > eps Estimate
-
Earnings History > 25 > eps Difference
0
Earnings History > 25 > surprise Percent
-
Earnings History > 26 > period
2019-09-30
Earnings History > 26 > report Date
2019-09-30
Earnings History > 26 > date
2019-09-30
Earnings History > 26 > before After Market
-
Earnings History > 26 > currency
-
Earnings History > 26 > eps Actual
0.589
Earnings History > 26 > eps Estimate
-
Earnings History > 26 > eps Difference
0
Earnings History > 26 > surprise Percent
-
Earnings History > 27 > period
2019-06-30
Earnings History > 27 > report Date
2019-06-30
Earnings History > 27 > date
2019-06-30
Earnings History > 27 > before After Market
-
Earnings History > 27 > currency
-
Earnings History > 27 > eps Actual
0.4843
Earnings History > 27 > eps Estimate
-
Earnings History > 27 > eps Difference
0
Earnings History > 27 > surprise Percent
-
Earnings History > 28 > period
2019-03-31
Earnings History > 28 > report Date
2019-03-31
Earnings History > 28 > date
2019-03-31
Earnings History > 28 > before After Market
-
Earnings History > 28 > currency
-
Earnings History > 28 > eps Actual
0.4714
Earnings History > 28 > eps Estimate
-
Earnings History > 28 > eps Difference
0
Earnings History > 28 > surprise Percent
-
Earnings History > 29 > period
2018-12-31
Earnings History > 29 > report Date
2018-12-31
Earnings History > 29 > date
2018-12-31
Earnings History > 29 > before After Market
-
Earnings History > 29 > currency
-
Earnings History > 29 > eps Actual
0.3197
Earnings History > 29 > eps Estimate
-
Earnings History > 29 > eps Difference
0
Earnings History > 29 > surprise Percent
-
Earnings History > 30 > period
2018-09-30
Earnings History > 30 > report Date
2018-09-30
Earnings History > 30 > date
2018-09-30
Earnings History > 30 > before After Market
-
Earnings History > 30 > currency
-
Earnings History > 30 > eps Actual
0.1351
Earnings History > 30 > eps Estimate
-
Earnings History > 30 > eps Difference
0
Earnings History > 30 > surprise Percent
-
Earnings History > 31 > period
2018-06-30
Earnings History > 31 > report Date
2018-06-30
Earnings History > 31 > date
2018-06-30
Earnings History > 31 > before After Market
-
Earnings History > 31 > currency
-
Earnings History > 31 > eps Actual
0.2436
Earnings History > 31 > eps Estimate
-
Earnings History > 31 > eps Difference
0
Earnings History > 31 > surprise Percent
-
Earnings History > 32 > period
2018-03-31
Earnings History > 32 > report Date
2018-03-31
Earnings History > 32 > date
2018-03-31
Earnings History > 32 > before After Market
-
Earnings History > 32 > currency
-
Earnings History > 32 > eps Actual
-0.1943
Earnings History > 32 > eps Estimate
-
Earnings History > 32 > eps Difference
0
Earnings History > 32 > surprise Percent
-
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI (ruxolitinib) for the treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for treating relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a selective fibroblast growth factor receptor kinase inhibitor for the treatment of unresectable biliary tract cancer, metastatic cholangiocarcinoma, and myeloid/lymphoid neoplasms; ICLUSIG (ponatinib), a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma; and NIKTIMVO (axatilimab-csfr) for treating chronic graft-versus-host disease, as well as OPZELURA (ruxolitinib) cream for treating atopic dermatitis. Its clinical stage products include INCB123667 (CDK2) for ovarian cancer; INCB161734 (KRASG12D) for cancers; INCA33890 (TGFßR2xPD-1) for solid tumors; Ruxolitinib cream for mild to moderate hidradenitis suppurativa (HS); Povorcitinib for HS, nonsegmental vitiligo, prurigo nodularis, and asthma and chronic spontaneous urticaria; INCB000262 (MRGPRX2) and INCB000547 (MRGPRX4) for systemic immune and neuro-immune disorders; INCA034460 (anti-CD122) for vitiligo; and Zilurgisertib (ALK2) for fibrodysplasia ossificans progressive. It has collaboration with Genesis Therapeutics, Inc. The company sells its products to specialty and retail pharmacies, hospital pharmacies, and specialty distributors and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.
Stock Price
$0.00
increase compared to yesterday.
Dividend
Frequency:
Rate:
N/ANext Payout:
N/A(Last Updated 2025-09-30)
Health Score
Price to Earnings Ratio (P/E)
-
Very High
Low ≥ 50
High ≤ 10
Price to Book Ratio (P/B)
-
Very High
Low ≤ 1
High ≥ 3
Return on Equity (ROE)
-
Low
Low ≤ 5%
High ≥ 25%
Return on Assets (ROA)
-
Medium
Low ≤ 2%
High ≥ 10%
Free Cash Flow - Revenue % (FCF)
-
Very High
Low ≤ 5%
High ≥ 15%
Debt to Equity
-
Very High
Low ≥ 1
High ≤ 0.3
* Institutions hold a combined 0.00% of the total shares of Incyte Corp.
* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.
Date
2025-12-31
EPS Estimate
1.89
Date
2025-09-30
EPS Actual
2.1058
EPS Estimate
1.64
EPS Difference
0.4658
Surprise Percent
28.4024%
(Last Updated 2025-09-30)
(Last Updated 2025-09-30)
Revenue
$ 0
Cost Of Revenue
$ 0
Gross Profit
$ 0
Operating Expenses
$ 0
Operating Income
$ 0
Interest Expense
$ 0
Pretax Income
$ 0
Net Income
$ 0
Income Tax Expense
$ 0
EBITDA
$ 0
Total Other Income Expense Net
$ 0
Earnings Per Share
0
Dividends Per Share
0
Shares Outstanding
0
Operating Margin
0%
(Last Updated 2025-09-30)
Cash
$ 0
Short Term Investments
$ 0
Receivables
$ 0
Inventories
$ 0
Total Current Assets
$ 0
Property Plant Equipment
$ 0
Total Assets
$ 0
Payables
$ 0
Short Term Debt
$ 0
Long Term Debt
$ 0
Total Liabilities
$ 0
Equity
$ 0
(Last Updated 2025-09-30)
Net Income
$ 0
Depreciation
$ 0
Change In Working Capital
$ 0
Cash From Operations
$ 0
Capital Expenditures
$ 0
Cash From Investing
$ 0
Cash From Financing
$ 0
Net Change In Cash
$ 0
Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.